Kidney CancersNCT07713654
Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct Radiological-histopathological Correlation: an Explorative Study
A study testing mpMRI in people with Kidney Cancers, run by University of Zurich at 1 site in Switzerland.
Trial summary
In this study, high-resolution magnetic resonance imaging scans (MRI/mpMRI) were performed before surgical removal of the tumor and then compared with microscopic examinations of the tumor. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Cancers
- What is being tested?
- mpMRI
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9 participants
- Where
- 1 siteSwitzerland
- Study dates
- 2 Aug 2023to 10 Jul 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with confirmed or suspected renal tumor with an approx. size of ≥ 2 cm who are scheduled for clinical MRI examination and surgical resection of the tumor
- Informed consent as documented by signature (Informed Consent Form)
- Patients ≥18 years of age
Who cannot join
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study and lack of safe contraception
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
- Previous enrolment into the current study
- Enrolment of the investigator, his/her family members, employees and other dependent persons
- Patients with non-MRI compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-MRI compatible implants).
- Patients with known hypersensitivity reactions to MRI contrast agents will undergo the examination without application of a contrast agent
Trial locations and contacts
1 site in 1 country.
About this study
In this study, high-resolution magnetic resonance imaging scans (MRI/mpMRI) were performed before surgical removal of the tumor and then compared with microscopic examinations of the tumor. Instead of looking at just one single area, the study compared many small, spatially correlated sections of the tumor-almost like creating a mini-map of the entire tumor.
Read the detailed description
A prospective single-center pilot study was performed on patients with solid renal tumors ≥2cm undergoing nephrectomy. Each patient underwent advanced preoperative 3.0T-mpMRI (including T2-weighted, pre-/postcontrast T1-weighted sequences, CS imaging, IVIM-DWI, and mapping). Tumor regions were jointly defined by a pathologist and radiologist. Identical Regions of Interest (ROIs) were assessed across all sequences to derive quantitative mpMRI parameters. Histopathology provided quantified regional fractions: viable tumor, fibrosis, hemorrhage, and cystic/necrotic components. Associations between these parameters were evaluated using Spearman's rank correlation and univariable linear regression at the regional level.
- Conditions
- Kidney Cancers
- Being tested
- mpMRI
- Keywords
- Magnetic Resonance Imaging
- Medical subject headings
- Kidney Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mpMRIDiagnostic test
Multiparametric MRI prior to nephrectomy
| Study group | Role | What they receive |
|---|---|---|
| Single Arm (MRI) | Experimental | mpMRI prior to nephrectomy Receives: Diagnostic Test: mpMRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation Viable Tumor Fraction With Contrast Enhancement Change
Correlation between viable tumor fraction and change in tumor contrast enhancement on MRI
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start2 Aug 2023
- Primary completion7 Jul 2025
- Study completion10 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Kidney CancersStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07713654
- Sponsor's protocol ID
- mpMRI RCC
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 28 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct Radiological-histopathological Correlation: an Explorative Study
- ClinicalTrials.gov ID
- NCT07713654
- Acronym / sponsor ID
- mpMRI RCC
- Conditions
- Kidney Cancers
- Keywords
- Magnetic Resonance Imaging
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 2 Aug 2023 (actual)
- Primary completion
- 7 Jul 2025 (actual)
- Study completion
- 10 Jul 2025 (actual)
- First posted
- 20 Jul 2026 (actual)
- Results
- Posted 28 Oct 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, high-resolution magnetic resonance imaging scans (MRI/mpMRI) were performed before surgical removal of the tumor and then compared with microscopic examinations of the tumor. Instead of looking at just one single area, the study compared many small, spatially correlated sections of the tumor-almost like creating a mini-map of the entire tumor.
Detailed description
A prospective single-center pilot study was performed on patients with solid renal tumors ≥2cm undergoing nephrectomy. Each patient underwent advanced preoperative 3.0T-mpMRI (including T2-weighted, pre-/postcontrast T1-weighted sequences, CS imaging, IVIM-DWI, and mapping). Tumor regions were jointly defined by a pathologist and radiologist. Identical Regions of Interest (ROIs) were assessed across all sequences to derive quantitative mpMRI parameters. Histopathology provided quantified regional fractions: viable tumor, fibrosis, hemorrhage, and cystic/necrotic components. Associations between these parameters were evaluated using Spearman's rank correlation and univariable linear regression at the regional level.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm (MRI) | Experimental | Diagnostic Test: mpMRImpMRI prior to nephrectomy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with confirmed or suspected renal tumor with an approx. size of ≥ 2 cm who are scheduled for clinical MRI examination and surgical resection of the tumor
- Informed consent as documented by signature (Informed Consent Form)
- Patients ≥18 years of age
Key exclusion criteria (7 listed)
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study and lack of safe contraception
- Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant
- Previous enrolment into the current study
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mpMRIMultiparametric MRI prior to nephrectomy | Diagnostic test | Single Arm (MRI) |
Primary outcome
Correlation Viable Tumor Fraction With Contrast Enhancement Change
Time frame: Baseline
Correlation between viable tumor fraction and change in tumor contrast enhancement on MRI
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Kidney Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing mpMRI in people with Kidney Cancers, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation Viable Tumor Fraction With Contrast Enhancement Change (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.